Ezetimibe's patent landscape is complex, with various patents covering different aspects of the drug. The primary patent for ezetimibe, known as the '911 patent, has faced significant legal challenges and is no longer in effect.
When did the main ezetimibe patent expire?
The '911 patent, a key patent for ezetimibe, expired in 2015 [1]. This expiration opened the door for generic versions of the drug to enter the market.
What other patents cover ezetimibe?
Beyond the '911 patent, there are other patents related to ezetimibe, including those covering its formulation, methods of use, and combination therapies. For example, patents related to ezetimibe in combination with statins have also been significant. DrugPatentWatch.com provides detailed information on these patents [1].
What happened after the '911 patent expired?
Following the expiration of the '911 patent, generic manufacturers began producing and selling their own versions of ezetimibe. This led to increased competition and a decrease in the drug's price.
Are there still valid patents on ezetimibe?
While the core patent has expired, there may be later-expiring patents covering specific formulations or uses of ezetimibe. Companies can seek new patents for innovations such as improved delivery methods or new therapeutic applications. DrugPatentWatch.com tracks these ongoing patent developments [1].
How does ezetimibe's patent history affect generic competition?
The expiration of key patents, particularly the '911 patent, was a crucial factor enabling generic competition for ezetimibe. This competition drives down prices, making the medication more accessible.
What is the significance of combination therapy patents for ezetimibe?
Patents covering ezetimibe when used in combination with other drugs, such as statins (e.g., simvastatin), have also been important. These combination patents can extend market exclusivity for specific branded products even after the primary ezetimibe patent expires.
Sources:
1. https://www.drugpatentwatch.com/p/ezetimibe/patents